Literature DB >> 6846746

Nasal inhalation as a cause of inefficient pulmonal aerosol inhalation technique in children.

S Pedersen, P A Ostergaard.   

Abstract

In order to evaluate whether children can be taught the efficient use of a pressurized terbutaline aerosol with a tube spacer 71 children were given careful instruction in aerosol inhalation technique according to the manufacturer's instructions. Inhalation technique was assessed as being efficient when a child achieved an increase of more than 19% in FEV1 10 min after taking two puffs of terbutaline (each puff = 0.25 mg). After instruction about 37% of children aged 5-7 years and about 80% of children over 7 years were efficient in inhalation technique. Inhalation through the nose after actuation into the mouth accounted for about 50% of treatment failures, with the problem being more frequent in the younger age group. When this error was corrected about 83% of the children were efficient in the technique. Coordination problems and too rapid inspiration after actuation were also common errors. The findings stress the importance of checking all children's inhalation technique before prescribing inhalation therapy. Careful instruction was not enough. The possibility of nasal inhaling should be borne in mind when looking for causes of treatment failure.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6846746     DOI: 10.1111/j.1398-9995.1983.tb01605.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  4 in total

Review 1.  Nebuliser therapy in childhood.

Authors:  P W Barry; C O'Callaghan
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

Review 2.  Addressing the Regulatory and Scientific Challenges with Generic Orally Inhaled Drug Products.

Authors:  Bryan Newman; Kimberly Witzmann
Journal:  Pharmaceut Med       Date:  2020-04

3.  Influence of spacer device on drug delivery to young children with asthma.

Authors:  L Agertoft; S Pedersen
Journal:  Arch Dis Child       Date:  1994-09       Impact factor: 3.791

4.  Development of Respimat(®) Soft Mist™ Inhaler and its clinical utility in respiratory disorders.

Authors:  Richard N Dalby; Joachim Eicher; Bernd Zierenberg
Journal:  Med Devices (Auckl)       Date:  2011-09-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.